Home
HelpTest ID BLOD0849 Alpha-Fetoprotein (AFP) Tumor Marker, Serum
Reporting Name
Alpha-Fetoprotein, Tumor Marker, SUseful For
Follow-up management of patients undergoing cancer therapy, especially for testicular and ovarian tumors and for hepatocellular carcinoma
Often used in conjunction with human chorionic gonadotropin.(2)
This test is not recommended as a screening procedure for cancer detection in the general population.
This test is not intended for the detection of neural tube defects.
This test is not useful for patients with pure seminoma or dysgerminoma.
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
SerumOrdering Guidance
This test is used as a tumor marker and is not intended for the detection of neural tube defects. For testing amniotic fluid specimens, order AFPA / Alpha-Fetoprotein, Amniotic Fluid.
Specimen Required
Collection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.6 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 7 days | |
| Frozen | 90 days |
Special Instructions
Reference Values
<8.4 ng/mL
Reference values are for nonpregnant subjects only; fetal production of alpha-fetoprotein elevates values in pregnant women.
Range for newborns is not available, but concentrations over 100,000 ng/mL have been reported in normal newborns, and the values rapidly decline in the first 6 months of life.(See literature reference: Ped Res 1981;15:50-52) For further interpretive information, see Alpha-Fetoprotein (AFP)
Serum markers are not specific for malignancy, and values may vary by method.
Day(s) Performed
Monday through Friday
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
82105
Report Available
1 to 3 daysReject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
Method Name
Immunoenzymatic Assay
Forms
If not ordering electronically, complete, print, and send Oncology Test Request (T729) with the specimen.
Secondary ID
8162Sanford Interface Build Information
| Result Code | Result Code Description |
|---|---|
| 17111 | Recalculated Maternal Serum Screen |
| 22806 | Results Summary |
| 228074 | Neural Tube Defect Risk Estimate |
| 17134 | AFP |
| 22808 | AFP Mom |
| 17141 | Interpretation |
| 17143 | Recommended Follow Up |
| 17142 | Additional Comments |
| 17112 | Collection Date |
| 17113 | Birthdate |
| 17114 | Calculated Age at EDD |
| 17115 | Maternal Weight |
| 17116 | Maternal Weight |
| 17117 | Insulin Dependent Diabetes |
| 22813 | Patient Race |
| 22814 | Current Cigarette Smoking Status |
| 17123 | EDD by U/S Scan |
| 17130 | GA on Collection by U/S Scan |
| 17125 | Edd by LMP |
| 17131 | GA on Collection by Dates |
| 17133 | GA Used in Risk Estimate |
| 17119 | Number of Fetuses |
| 22815 | Number of Chorions |
| 17120 | IVF Pregnancy |
| 22817 | Prev Pregnancy W/Neural Tube Defect |
| 22818 | Patient or Father of Baby has a NTD |
| 22819 | Initial or Repeat Testing |
| 22820 | Physician Phone Number |
| 17144 | General Test Information |